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Abstract
Background: ICI 182,780 (ICI) belongs to a new class of antiestrogens developed to be pure
estrogen antagonists and, in addition to its therapeutic use, it has been used to knock-out estrogen
and estrogen receptor (ER) actions in several mammalian species. In the present study, the effects
and mechanism of action of ICI were investigated in the teleost fish, sea bream (Sparus auratus).
Methods: Three independent in vivo experiments were performed in which mature male tilapia
(Oreochromis mossambicus) or sea bream received intra-peritoneal implants containing estradiol-
17 beta (E2), ICI or a combination of both compounds. The effects of E2 and ICI on plasma calcium
levels were measured and hepatic and testicular gene expression of the three ER subtypes, ER
alpha, ER beta a and ER beta b, and the estrogen-responsive genes, vitellogenin II and choriogenin
L, were analyzed by semi-quantitative RT-PCR in sea bream.
Results: E2 treatment caused an increase in calcium levels in tilapia, while ICI alone had no
noticeable effect, as expected. However, pretreatment with ICI synergistically potentiated the
effect of E2 on plasma calcium in both species. ICI mimicked some E2 actions in gene expression
in sea bream liver upregulating ER alpha, vitellogenin II and choriogenin L, although, unlike E2, it did
not downregulate ER beta a and ER beta b. In contrast, no effects of E2 or ICI alone were detected
in the expression of ERs in testis, while vitellogenin II and choriogenin L were upregulated by E2
but not ICI. Finally, pretreatment with ICI had a synergistic effect on the hepatic E2 down-
regulation of ER beta b, but apparently blocked the ER alpha up-regulation by E2.
Conclusion: These results demonstrate that ICI has agonistic effects on several typical estrogenic
responses in fish, but its actions are tissue-specific. The mechanisms for the ICI agonistic activity
are still unknown; although the ICI induced up-regulation of ER alpha mRNA could be one of the
factors contributing to the cellular response.
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Most estrogen actions are mediated by specific nuclear
estrogen receptors (ERs), which classically regulate tran-
scription by binding as dimers to specific estrogen-
response elements (ERE) found in promoters of estrogen-
responsive genes (ERGs) [1]. This transcriptional activity
is dependent on conformational changes of the ERs two
activation functions (AF): the N-terminal (ligand-inde-
pendent) AF-1 and the C-terminal (ligand-dependent)
AF-2, which function independently or synergistically to
recruit and interact with coregulator (coactivator or core-
pressor) proteins leading to changes in the rate of gene
transcription [2]. Two ER subtypes (α and β) are present
in most vertebrates, although in teleost fish one ERα and
two ERβ genes (βa and βb) have been identified [e.g. [3-
5]].
There is also substantial evidence that estrogens also func-
tion via non-classical mechanisms [1]. These include indi-
rect transcriptional activation through interaction of
ligand-bound ER with other transcription factors, ER lig-
and-independent activation in response to intracellular
signaling cascades, and rapid non-genomic actions initi-
ated at the plasma membrane. However, it is not clear if
these are mediated by a subset of nuclear ERs that localize
to the plasma membrane, or by novel membrane recep-
tors unrelated to ER or through both [1,6,7].
ERs are known to accept a wide range of ligands, including
natural estrogens, synthetic estrogens or antiestrogens,
phytoestrogens and a variety of xenoestrogens [8]. While
many behave as estrogen agonists, other compounds may
act either as agonists or antagonists depending on the spe-
cies, tissue, promoter or ER subtype (the selective ER mod-
ulators, SERMs; e.g. tamoxifen) [9]. The tissue-selective
effects of SERMs have been exploited to develop new
drugs for the treatment of estrogen-related diseases,
although some have unwanted side effects or generate
resistance to treatment, in part due to their agonist effects
in some tissues [10].
ICI 182,780 (trade names Faslodex, Fluvestrant) belongs
to a new class of antiestrogens developed to have no ago-
nistic effects, and besides its therapeutic potential demon-
strated in clinical trials, it has been used as an alternative
and efficient means to "knock-out" ER effects in studies of
estrogen functions, and to establish the contribution of
nuclear ERs to particular estrogen actions [11-14]. In
mammals, ICI 182,780 appears to act at several levels to
block estrogen actions [reviewed by [11,15]], but little is
known about its effects and mechanisms of action in fish.
ICI blocked E2-induced interstitial cell proliferation in
immature rainbow trout (Oncorhynchus mykiss) testis [16]
and the production of zona radiata proteins and vitello-
genin in Atlantic salmon (Salmo salar) hepatocytes [17]
and of vitellogenin in channel catfish (Ictalurus punctatus)
[18] and Siberian sturgeon (Acipenser baerii) [19] hepato-
cytes. Agonistic actions have been identified in Atlantic
croaker (Micropogonias undulatus), in which both estra-
diol-17β (E2) and ICI decreased gonadotropin-stimulated
11-ketotestosterone production in testicular fragments in
vitro, although these rapid effects appeared to be mediated
by interaction with membrane-bound receptors [20,21].
The objective of this study was to investigate the effects
and mechanisms of action of ICI 182,780 (ICI) on several
typical in vivo estrogenic responses in the teleost fish sea
bream (Sparus auratus), in order to evaluate the potential
of ICI as an agent to knock-out estrogen effects in fish. In
a preliminary experiment with the more readily available
tilapia (Oreochromis mossambicus) we established that ICI
potentiated the calciotropic effect of E2 [22-24]. The
effects of E2 and ICI on plasma calcium and on hepatic
and testicular gene expression of the three ER subtypes
and the estrogen-responsive genes vitellogenin II and cho-
riogenin L (egg yolk and eggshell precursors, respectively)
were then analyzed in sea bream, for which these molecu-
lar markers were available [5,25].
Methods
Fish
All animal maintenance and handling procedures were
carried out in compliance with the recommendations of
the Association of Animal Behavior [26]. Adult tilapia
were obtained from a stock raised from fertilized eggs at
the University of Algarve, Faro, Portugal, and maintained
in 150L closed circuit freshwater aquaria at a water tem-
perature of 24°C and 12L:12D (light-dark) photoperiod.
Adult sea bream were obtained from TIMAR Cultura de
Águas (Olhão, Portugal) and maintained at the University
of Algarve in through-flow 500L seawater tanks with a
water temperature of 17–21°C, 36‰ salinity and
12L:12D photoperiod. At least one weak before the start
of each experiment, fish were randomly distributed
between different tanks (one per treatment) and left to
acclimatize during this period.
Treatments and sampling
Three independent experiments were performed (see
additional file 1 for a representation of the experimental
design of the three experiments), in which anaesthetized
tilapia or sea bream (2-phenoxyethanol, Sigma-Aldrich,
Madrid, Spain, diluted 1:10,000 in seawater) received
intra-peritoneal (i.p.) implants of coconut oil (200 μl/100
g body weight, Sigma-Aldrich) containing different doses
of E2 (Sigma-Aldrich) and/or of ICI 182,780 (Tocris,
Cookson Ltd, Bristol, UK). Fish were returned to their
tanks and left undisturbed during the experimental period
(1–11 days), during which they were fed daily at the nor-
mal rate.Page 2 of 11
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test the broad effects of ICI on plasma calcium, the con-
centration of which typically increases in response to
estrogen [23,24]. Tilapia was chosen because we can easily
obtain reproductively mature individuals all year round.
The experiment was carried out in June/July with five
groups, each composed of five sexually mature male tila-
pia (body weight 45.9 ± 3.6 g). The effect of ICI alone
compared to control fish was tested in two groups in
which i.p. implants of coconut oil containing 35 mg/kg
body weight (bw) (I35 group) or the vehicle coconut oil
alone (CTL, control group) were administered. Since it
was expected that ICI would act as an E2 antagonist, we
hypothesized that pre-treatment with ICI should inhibit
the response to E2 including a lower calciotropic response
to E2. To test this hypothesis three further groups of fish
were pre-treated with either coconut oil vehicle, 35 mg/kg
bw ICI or 10 mg/kg bw ICI in coconut oil, followed 3 days
later by 10 mg/kg bw E2 in coconut oil (groups E, I35E3d
and I10E3d, respectively). The CTL and I35 groups were
also injected at this time with coconut oil alone. At each
sampling point (days 3, 5 and 11), fish were anesthetized
and blood samples collected from the caudal vein with
heparinized (150 U/ml ammonium heparin, Sigma-
Aldrich) 1 ml syringes. Plasma samples were obtained by
centrifugation of whole blood (10,000 rpm for 5 min)
and were stored at -20°C until the determination of
plasma calcium levels.
Since the tilapia experiment demonstrated a significant
agonistic effect of ICI, we have carried out an experiment
in sea bream (sea bream experiment 1, see additional file
1 for a representation of the experimental design) to com-
pare the gene expression in response to ICI or E2 at the
dosage levels used in tilapia. The sea bream was chosen
because we have available a range of molecular markers
for estrogen responsive genes [5,25]. The experiment was
carried out in September, at the beginning of spermiation,
with three groups of eight mature male sea bream (body
weight 367.1 ± 8.9 g) which received i.p. implants of coco-
nut oil containing 10 mg/kg bw E2 (E group), 10 mg/kg
bw ICI (I group) or coconut oil alone (CTL, control
group). Twenty eight hours later, fish were over-anesthe-
tized in 1:5,000 2-phenoxyethanol:seawater, killed by
decapitation and transverse sections of testis and liver
were collected, snap frozen in liquid nitrogen and stored
at -80°C for subsequent RNA extraction.
In the third experiment, carried out in November (sea
bream experiment 2, see additional file 1 for a representa-
tion of the experimental design), we set out to examine
the effect of lower, more physiologically relevant, dosages
of ICI and E2, separately or in combination, on plasma
calcium and gene expression in sea bream. For that pur-
pose six groups of eight mature spermiating male sea
bream (body weight 239.2 ± 3.3 g) were injected with the
vehicle (coconut oil) in the first day, except for group IE3d
which was injected with 4 mg/kg bw ICI in coconut oil.
After three days, fish were injected with coconut oil
implants containing 1 mg/kg bw E2 (E1 group), 0.1 mg/kg
bw E2 (E0.1 group), 4 mg/kg bw ICI (I group), 4 mg/kg bw
ICI plus 1 mg/kg bw E2 (IE group) or 1 mg/kg bw E2
(administrated to the IE3d group, injected with ICI in the
first day), while the control group (CTL) was injected with
coconut oil alone. Forty eight hours later, blood was col-
lected and plasma samples recovered as described above
and stored at -20°C until used for determination of cal-
cium and E2 (see below). Fish were killed by decapitation
and transverse sections of liver and testis sampled, frozen
in liquid nitrogen and stored at -80°C for subsequent
RNA extraction.
Quantification of E2 and calcium plasma levels
Total plasma calcium (bound plus free) was measured in
duplicate in 10 μl plasma samples from individual fish
using a colorimetric assay (Calcium kit, procedure
no.587, Sigma-Aldrich). E2 was quantified in individual
plasma samples by radioimmunoassay using specific
antiserum (Research Diagnostics, Flanders, New Jersey,
USA) as described in Guerreiro et al. [27]. The cross-reac-
tion of E2 antisera with ICI was approximately 20% in the
middle of the linear portion of the standard curve but
there was no parallelism with the standard curve of the
assay.
Semi-quantitative RT-PCR
Total RNA from male sea bream liver or testis was
extracted from frozen tissues using TRI Reagent (Sigma-
Aldrich) and cDNA was reverse transcribed from 4 μg of
total RNA using random primers and M-MLV reverse tran-
scriptase (Invitrogen, Carlsbad, CA, USA) in a 30 μl reac-
tion. The mRNA expression of sea bream ERs, vitellogenin
II (VgII), choriogenin L (ChgL) and the internal control
gene coding for 18S ribosomal RNA (18S) was analyzed
by semi-quantitative RT-PCR using the same reaction con-
ditions, primers and annealing temperatures previously
described by Pinto et al. [5,25]. These parameters are rep-
resented in Table 1, together with the cycle numbers opti-
mized for the detection of each gene in the exponential
phase of amplification for each experiment/tissue ana-
lyzed in this study. No genomic DNA or cross-annealing
with genes from the same family was detected with these
primers [5,25]. Band intensities of RT-PCR products were
quantified by densitometry as previously described [25]
and relative expression values calculated as base ten loga-
rithms of the expression ratios between each gene and
18S.Page 3 of 11
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Plasma calcium concentrations in the tilapia time-course
experiment were log transformed and analyzed by two-
way repeated-measures ANOVA, followed by a post-hoc
Tukey test for pairwise multiple comparison. Calcium and
E2 concentrations and semi-quantitative RT-PCR data (all
log transformed) in the sea bream experiments were ana-
lyzed by one-way ANOVA followed by the Tukey test.
Pearson correlations of expression levels among genes
were calculated and probabilities determined with Bon-
ferroni corrections. The software used in the analysis was
SigmaStat v.3.00 (SPSS Inc, Chicago, USA). Data is pre-
sented as mean ± standard error of the mean and statisti-
cal significance was established at P < 0.05.
Results
Effect of E2 and ICI 182,780 on plasma calcium in tilapia
As expected, after 2 days of E2 treatment tilapia plasma cal-
cium levels increased to almost twice those of the controls
(Figure 1). In contrast, there were no statistically signifi-
cant differences in calcium levels between control and ICI
only-treated tilapia. However, ICI-pretreatment at the two
doses tested strongly potentiated the effect of E2 on cal-
cium causing a highly significant ~2 fold increase within
two days and a further ~1.5 fold increase in the next 6 days
with the highest ICI dose (I35E3d).
Calcium and gene expression response to E2 and/or ICI 
182,780 treatment in sea bream
Since in the first experiment conducted in tilapia 10 and
35 mg ICI provoked a rise in calcium of similar magnitude
after three days of E2 exposure, 10 mg/kg ICI and 10 mg/
kg E2 treatments were used to investigate their short-term
effects (28 h) on gene expression in sea bream. As
expected, E2 treatment caused a significant up-regulation
in expression of ERα (approx. 4-fold), VgII (6-fold) and
ChgL (11-fold) in liver (Figure 2A). In contrast the mRNA
levels of both ERβ subtypes significantly decreased
approx. 10-fold compared to the control group. Interest-
ingly, treatment with ICI also caused a significant up-reg-
ulation in ERα, VgII and ChgL, which was of the same
magnitude to that of E2 treatment in the case of ERα but
significantly less in the case of VgII and ChgL (1.8- and
2.5-fold increase, respectively, compared to control). ICI
treatment had no effect on the expression of ERβa or βb.
Strong positive Pearson correlations were found between
the ERα, VgII and ChL responses to E2 and ICI in this tis-
sue (Pearson coefficient 0.658–0.939, P < 0.01), but not
between ERβa and ERβb.
In the testis, no statistically significant changes in gene
expression were obtained for any of the ER subtypes (Fig-
ure 2B), while the expression levels of both VgII and ChgL
were increased by E2 but remained unaltered by ICI treat-
ment. In contrast to what was observed in the liver, ERα
was positively correlated with ERβa (Pearson coefficient
0.640, P < 0.05) but not with VgII and ChgL, which were
highly correlated among them (0.853, P < 0.001).
In order to further investigate and confirm the obtained
effects of E2 and ICI on the different types of estrogenic
response, a second sea bream experiment was performed
Table 1: Primers used for gene expression analysis by RT-PCR
Cycle number(N)
Exp1 Exp2
Gene product Primer Sequence bp Ta (°C) Liv Tes Liv
Estrogen receptor α (ERα, AJ006039) 5'-CCCATCCAGTCAGCATTCA-3'
5'-TTGTCACGCCGCAGAACG-3'
374 57 25 25 25
Estrogen receptor βa (ERβa, AF136980) 5'-GCTGATGATCGGACTGATGTG-3'
5'-GGTGTACTGTTGGCGGAAAG-3'
348 59 27 23 29
Estrogen receptor βb (ERβb, AJ580049) 5'-TGATGATGTCACTCACCAACC-3'
5'-TTCAGCTCACGAAACCGA-3'
291 54 25 22 26
Choriogenin L (ChgL, CX734876) 5'-AGAGGGATGCTGTCGTAG-3'
5'-GTGATGCCTTTGGTAGTG-3'
290 56 25 30 18
Vitellogenin II (VgII, CX734956) 5'-CACTTGGCATTGGTCTCCC-3'
5'-ATGGTGCACTCAGCTGCATG-3'
130 58 20 25 18
18S ribosomal RNA (18S) 5'-TCAAGAACGAAAGTCGGAGG-3'
5'-GGACATCTAAGGGCATCACA-3'
495 59 18 18 15
Gene name abbreviation and accession number, primer sequence (forward and reverse, respectively), amplicon length (bp), annealing temperature 
(Ta) and optimized cycle numbers (N) for liver (Liv) or testis (Tes) cDNAs from Experiments (Exp) 1 and 2.Page 4 of 11
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mg/kg E2, 4 mg/kg ICI) in different combinations and
sampling conducted 48 h after E2 injection. Expression in
testis was not analyzed due to the lack of response to ICI
detected for ERs in sea bream experiment 1 and the high
variability among individuals in the VgII and ChL
response. Furthermore, the fish in the second sea bream
experiment were at a stage of more advanced maturity
(active spermiation) than in the first sea bream experi-
ment (early spermiation) making direct comparisons dif-
ficult. In contrast, the liver showed more consistent and
less variable results. To confirm the effectiveness of the
treatments with the lower levels of hormones, E2 plasma
levels were determined for each fish at the end of the
experiment. Control sea bream had circulating plasma E2
levels of 0.6 ± 0.2 ng/ml, while in E2-implant groups these
had increased 26-fold to 15.5 ± 4.0 ng/ml (E1 group) or
7-fold to 4.0 ± 0.6 ng/ml (E0.1). E2 plasma levels in the
ICI-implanted groups (4.6 ± 1.8 ng/ml for I, 27.6 ± 7.9 for
IE and 27.5 ± 7.0 for IE3d) were probably overestimated
due to cross-reaction. The levels of E2 achieved with the
implants are within the range observed in spawning sea
bream [28]
As for calcium levels, no significant difference was
detected between control fish and E2 at any dosage, ICI
alone or the simultaneous treatment with E2 and ICI (Fig-
ure 3). However, in common with tilapia, pretreatment
with ICI followed by E2 three days later (IE3d group)
caused a statistically significant increase in the plasma cal-
cium levels compared to control fish. A statistically signif-
icant difference between plasma calcium concentrations
in ICI treatment only and the IE3d treatment group was
also observed.
As in the previous experiment, the hepatic expression lev-
els of ERα were significantly increased by both doses of E2
and by ICI alone (Figure 4). Simultaneous administration
of ICI and E2 (IE group) also caused a significant increase
in the ERα expression levels, although it was not signifi-
cantly different from that obtained with the same dose of
E2 alone (E1). In contrast, in the group pretreated with ICI
(IE3d group), ERα transcript levels were not significantly
different from the control but differed from the E2 alone
group (E1), suggesting an inhibition of the E2-induced
ERα up-regulation.
For ERβa, no significant differences were detected
between the different treatments, although a decrease
compared to control was apparent for the lower dose of E2
(E0.1), ICI alone (I) and pretreatment with ICI followed
by E2 (IE3d) (Figure 4). Similarly, with ERβb there was a
trend for reduction in expression levels in response to all
the treatments, with only the combination of E2 and ICI
(IE and IE3d groups), significantly decreasing the expres-
sion level of this gene compared to the control, and with
IE3d also decreasing it in comparison to the E2 only-
treated groups (E1 and E0.1). The expression of both VgII
and Chg was significantly increased by both doses of E2
and combined E2/ICI treatments, while no change in
expression could be detected in the group treated with ICI
alone. Strong positive Pearson correlations were found
between the ERα, VgII and ChL response (Pearson coeffi-
cients 0.466–0.981, P < 0.01) and between ERβa and
ERβb (Pearson coefficient 0.679, P = 0.00), while negative
correlations were found between the response of ERβb
and both VgII and ChgL (coefficients -0.435 and -0.398,
respectively, P < 0.05).
Discussion
This study demonstrated that, at least in fish, ICI does not
always function as an anti-estrogen since it did not block
the effects of an E2 challenge. Indeed, prior administration
of ICI potentiated the response to E2. Furthermore, the
agonistic response to ICI could also be detected at the
Time-course of total calcium plasma response in tilapiaF gure 1
Time-course of total calcium plasma response in tila-
pia. Adult male tilapia received coconut oil implants with dif-
ferent combinations of estradiol (E2) and of the antiestrogen 
ICI 182,780 (ICI). Times of injection are represented by 
arrows on the lower panel. CTL = control group, coconut oil 
only; E = 10 mg/kg body weight E2; I35 = 35 mg/kg ICI; I35E3d 
and I10E3d = 10 mg/kg E2 injected three days after injection 
with 35 or 10 mg/kg ICI, respectively. Blood samples were 
collected 3, 5 and 11 days after the first injection. Different 
letters indicate statistically significant differences (P < 0.05) 
among treatments and sampling times, evaluated by two-way 
repeated-measures ANOVA using log10 of calcium plasma 
levels.Page 5 of 11
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Gene expression in E2-treated (high dose) sea breamFigur  2
Gene expression in E2-treated (high dose) sea bream. Sea bream males received coconut oil implants with 10 mg/kg 
body weight E2 (E), 10 mg/kg ICI (I) or coconut oil alone (CTL) for 28 h. Liver (A and C) and testis (B and D) were analyzed 
for gene expression of estrogen receptors (ERα, ERβa, ERβb) and estrogen-responsive genes, vitellogenin (VgII) and chorio-
genin (ChgL) by semi-quantitative RT-PCR. Each bar (A and B) is the mean ± S.E.M. of the relative expression values (target 
gene/18S) of eight fish. Different letters indicate statistically significant differences between treatments (general linear model 
using log10 of the relative expression values, P < 0.05). The gel images (C and D) are representative RT-PCR products for each 
experimental group.
Reproductive Biology and Endocrinology 2006, 4:67 http://www.rbej.com/content/4/1/67level of gene expression and was different in liver and tes-
tis.
The level of total calcium in plasma is known to correlate
with Vg protein and E2 plasma levels in females during
vitellogenesis and in males in response to E2 exposure,
and it is thus used as a vitellogenesis marker [22-24]. The
lack of a statistically significant calcium elevation with E2
treatment alone in sea bream was probably due to the low
doses and/or exposure time compared to previous sea
bream experiments (>4 days, 10 mg/kg) [27] and to the
tilapia experiment (>48 h, 10 mg/kg). ICI alone did not
change total plasma calcium levels or may have slightly
lowered calcium within 48 h (Figures 1 and 3), consistent
with an antagonistic action. However, pretreatment with
ICI synergistically potentiated the hypercalcemic effect of
E2 in both sea bream and tilapia. This observation seems
to indicate that the initial binding of ICI to ER effectively
blocks ER binding to target genes (antiestrogenic action)
in the liver, but subsequently E2 triggers a disproportion-
ate agonistic response. Whether ICI acts by stimulating ER
synthesis or at the level of ER responsiveness is not clear.
In support for the first possibility is the fact that ERα levels
in the liver of fish treated with ICI are upregulated and at
similar levels to the E2-treated fish. However, it is surpris-
ing that ERα levels in E2 challenged fish after pretreatment
with ICI are no higher than fish treated with ICI only (Fig-
ure 4). Analysis of the early time-course changes in this
response is required to clarify the possible mechanism
involved.
The ERα, VgII and ChgL up-regulation by E2 in liver is in
accordance with our previous observations [25]. ERα
autoregulation in liver is a common characteristic of ovip-
arous animals [e.g. [29-32]] that has been attributed to ER
involvement in the production of egg yolk and egg shell
precursors vitellogenins and choriogenins, respectively, in
the liver of mature females in response to E2. In contrast
to ERα, the regulation of ERβ genes by estrogen is poorly
investigated and appears to be much more variable, with
these genes being either slightly up- or down-regulated
depending on the species and ER subtype [33,34]. In this
study, the expression of both ERβa and ERβb are strongly
down-regulated by E2 in liver in the first sea bream exper-
iment, and only slightly down-regulated in the second
experiment in which lower doses are used, possibly indi-
cating that their regulation is dose-dependent (and less
sensitive to E2 than ERα). These results indicate a differen-
tial estrogen regulation of sea bream ERα and ERβ genes
in liver and support the hypothesis that the role of the ERβ
forms, in the transcriptional regulation of genes associ-
ated with reproduction in fish liver is probably less impor-
tant than that of the ERα subtype and may depend on the
life stage of the fish and/or the species. In contrast to the
liver, a slight up-regulation by E2 of both ERα and ERβb
but not ERβb is detected in testis, suggesting the regula-
tion of ER subtypes varies among tissues, while the up-reg-
ulation of VgII and ChgL confirms its recent identification
as ERGs in this tissue [25].
ICI mimicked the E2 effects in the liver, up-regulating ERα,
VgII and ChgL in sea bream liver, but not in the testis and
unlike E2 it did not down-regulate the two ERβ subtypes in
liver, supporting tissue- and gene-specific effects for this
compound. The simultaneous administration of ICI with
E2 did not block the E2 effects on the expression of any of
the genes, neither did the ICI pretreatment in the E2-
induced up-regulation of ChgL and VgII, suggesting that
ICI did not act as an antagonist. However, ICI pretreat-
ment synergistically potentiated the E2 down-regulation
of the ERβb gene, while it appeared to have an inhibitory
effect on the E2 up-regulation of ERα (Figure 4), at least in
the time-frame and doses analyzed (see above).
Taken together, these results contrast with the conven-
tional classification of ICI as a "pure estrogen antagonist",
which has been reported to block the effects of E2 and
some partial agonists (e.g. tamoxifen) with no detected
agonistic activities in several in vivo and in vitro models of
estrogen action in different mammalian species [reviewed
by [11,35]]. However, some recent in vitro studies have
also reported agonistic or partial agonistic activities for ICI
Total calcium plasma levels in sea breamFigure 3
Total calcium plasma levels in sea bream. Sea bream 
males were sampled two days after receiving coconut oil 
implants containing 1 mg/kg body weight E2 (E1), 0.1 mg/kg E2 
(E0.1), 4 mg/kg ICI (I), 4 mg/kg ICI plus 1 mg/kg E2 (IE), 1 mg/
kg E2 in addition to 4 mg/kg ICI (IE3d) 3 days earlier, or coco-
nut oil alone (CTL). Each bar is the mean ± S.E.M of the cal-
cium plasma levels (mM) of eight fish. Different letters 
indicate statistically significant differences (P < 0.05) between 
treatments, evaluated by one-way ANOVA using log10 of cal-
cium plasma levels.Page 7 of 11
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Gene expression in E2-treated (low doses) sea breamFigur  4
Gene expression in E2-treated (low doses) sea bream. Semi-quantitative RT-PCR of estrogen receptors (ERα, ERβa, 
ERβb) and estrogen-responsive genes, vitellogenin (VgII) and choriogenin (ChgL), in male sea bream liver (see Figure 3 for 
group abbreviations) 48 h following treatment. Each bar (A) is the mean ± S.E.M. of the relative expression values (target gene/
18S) of eight fish. Different letters indicate statistically significant differences between treatments (general linear model using 
log10 of the relative expression values, P < 0.05). The gel images (B) are representative RT-PCR products for each experimen-
tal group.
Reproductive Biology and Endocrinology 2006, 4:67 http://www.rbej.com/content/4/1/67[36-40], which appear to depend on the species, the tis-
sue, the ER subtype and the promoter, as reported for
other SERMs.
The mechanisms in place for the agonistic effects in fish
are as yet unknown. Most antiestrogens act through com-
petitive binding to ERs and induction of an inactive con-
formation of the ligand-dependent AF-2 function of ERs,
and their context-specific agonistic activities have been
mainly attributed to a tissue- or promoter-specific activa-
tion of the ligand-independent AF-1 function or to the
induction of a partially active AF-2 conformation [41]. ICI
appears to act at several levels to completely block ER-
mediated actions (better studied for the ERα subtype),
including the competitive inhibition of agonist binding to
ERα, the inhibition of ER dimerization, nuclear transloca-
tion and transcription activation through both AF-1 and
AF-2, and increased ER protein degradation [reviewed by
[11,15]]. While estrogens are known to rapidly down-reg-
ulate the ERα and ERβ protein levels in several mamma-
lian cell types but up regulate its mRNA levels [42], ICI has
been shown to cause ERα protein degradation without
affecting the ERα mRNA levels [11], thereby leading to an
effective reduction of the ER protein levels. Possible expla-
nations for the partial ICI agonism are: 1) lack of ERα pro-
tein down-regulation, as observed in cells of the sheep
uterus or in human breast cancer cells; 2) species-specific
differences in the N- or C-terminal regions of ERs, which
could influence ligand discrimination; 3) ER activation
via non-classical mechanisms (e.g. non-genomic actions
and indirect activation at AP-1 promoters); 4) ICI activa-
tion of other ER subtypes (nuclear ERβ or membrane ERs)
or ER variant proteins whose relative expression depends
on the cell type or species [36-40]. In addition, it was
recently reported that ICI was able to promote human
ERα interaction with the CBP/p300 but not the p160 fam-
ily of coactivators in HeLa cells, although this was insuffi-
cient to promote transcription from the pS2 (an ERG)
promoter [43].
In fish, unlike in mammals, estrogens have been shown to
increase both ERα mRNA (through increased transcrip-
tion and enhanced stability) and ER protein levels in liver
[31,44,45]. The ICI up-regulation of ERα in liver detected
in the present study could contribute to the observed ago-
nistic effects, and the potentiation effects observed for the
ICI pretreatment may be due to an increased responsive-
ness of the tissue at the time of E2 administration through
sbERα up-regulation by ICI. Whether the ERα mRNA ICI
up-regulation is followed by an increase in ERα protein
level in liver, as occurs with E2, must be investigated in
future studies.
The inability of ICI to inhibit the up-regulation of ERα,
VgII and ChgL by E2 in fish liver (Figure 4) could also be
interpreted as evidence for an ER-independent mecha-
nism, as suggested for other ICI-insensitive actions [e.g.
[46]]. However, this appears not to be the case, since ICI
alone was able to up-regulate these genes (Figure 2) and
because the E2-induced transcriptional activation of both
ERα and VgII genes have been demonstrated to involve
binding of the ER proteins to specific response-elements
in their promoters [33,47,48], while the stabilization of
their mRNAs has also been shown to be mediated by E2/
ER complexes [44]. The dependence on ERα has also been
demonstrated in some studies reporting ICI agonism in
mammals by using ER-specific siRNA [39].
Conclusion
In conclusion, at least in fish, ICI does not always function
as an antiestrogen since it did not block the effects of an
E2 challenge on several typical estrogenic actions. Indeed,
prior administration of ICI strongly potentiated the
response of plasma calcium to E2. Furthermore, this ago-
nistic response to ICI could be detected at the level of gene
expression and was different in liver and testis. The strong
up-regulation of ERα in correlation with Vg and ChgL and
the down-regulation of both sbERβs confirm that ERα is
probably the most important ER subtype controlling liver
gene expression in response to E2.
The identified agonistic effects suggest caution in the use
of ICI as a pure antiestrogen to "knock-out" estrogen func-
tions in fish, at least until their effects and mechanisms of
action are better characterized. It would be also interesting
to investigate the effects of other "pure antagonists" such
as ICI 164,384 and RU 58668 on the estrogenic actions
analyzed in this study.
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